CLYM Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Climb Bio's net margin of --. Climb Bio's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Climb Bio has a consensus price target of $10.00, signalling upside risk potential of 747.46%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 478.3%. Given that Climb Bio has higher upside potential than Perspective Therapeutics, analysts believe Climb Bio is more attractive than Perspective Therapeutics.

Climb Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Climb Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Climb Bio quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Climb Bio's net income of -$20.8M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Climb Bio's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio is -- versus 16.84x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Mersana Therapeutics has a net margin of -- compared to Climb Bio's net margin of -875.93%. Climb Bio's return on equity of -- beat Mersana Therapeutics's return on equity of -533.43%.

Climb Bio has a consensus price target of $10.00, signalling upside risk potential of 747.46%. On the other hand Mersana Therapeutics has an analysts' consensus of $4.29 which suggests that it could grow by 1116.5%. Given that Mersana Therapeutics has higher upside potential than Climb Bio, analysts believe Mersana Therapeutics is more attractive than Climb Bio.

Climb Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mersana Therapeutics has a beta of 1.319, suggesting its more volatile than the S&P 500 by 31.945%.

Climb Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio pays -- of its earnings as a dividend. Mersana Therapeutics pays out -- of its earnings as a dividend.

Climb Bio quarterly revenues are --, which are smaller than Mersana Therapeutics quarterly revenues of $2.8M. Climb Bio's net income of -$20.8M is higher than Mersana Therapeutics's net income of -$24.1M. Notably, Climb Bio's price-to-earnings ratio is -- while Mersana Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio is -- versus 1.28x for Mersana Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma has a net margin of -- compared to Climb Bio's net margin of -436.62%. Climb Bio's return on equity of -- beat Sutro Biopharma's return on equity of -322.47%.

Climb Bio has a consensus price target of $10.00, signalling upside risk potential of 747.46%. On the other hand Sutro Biopharma has an analysts' consensus of $3.26 which suggests that it could grow by 254.04%. Given that Climb Bio has higher upside potential than Sutro Biopharma, analysts believe Climb Bio is more attractive than Sutro Biopharma.

Climb Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sutro Biopharma has a beta of 1.775, suggesting its more volatile than the S&P 500 by 77.488%.

Climb Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio pays -- of its earnings as a dividend. Sutro Biopharma pays out -- of its earnings as a dividend.

Climb Bio quarterly revenues are --, which are smaller than Sutro Biopharma quarterly revenues of $17.4M. Climb Bio's net income of -$20.8M is higher than Sutro Biopharma's net income of -$76M. Notably, Climb Bio's price-to-earnings ratio is -- while Sutro Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio is -- versus 1.14x for Sutro Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -- compared to Climb Bio's net margin of -479.24%. Climb Bio's return on equity of -- beat Voyager Therapeutics's return on equity of -26.82%.

Climb Bio has a consensus price target of $10.00, signalling upside risk potential of 747.46%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.00 which suggests that it could grow by 440.34%. Given that Climb Bio has higher upside potential than Voyager Therapeutics, analysts believe Climb Bio is more attractive than Voyager Therapeutics.

Climb Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.950, suggesting its less volatile than the S&P 500 by 5.041%.

Climb Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Climb Bio quarterly revenues are --, which are smaller than Voyager Therapeutics quarterly revenues of $6.5M. Climb Bio's net income of -$20.8M is higher than Voyager Therapeutics's net income of -$31M. Notably, Climb Bio's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio is -- versus 2.53x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.